Recombinant antibodies: From the laboratory to the clinic

被引：20

作者：

Albrecht, Huguette ^{[1
]}

DeNardo, Sally J. ^{[1
]}

机构：

[1] Univ Calif Davis, Med Ctr, Sacramento, CA 95816 USA

来源：

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2006年 / 21卷 / 04期

关键词：

recombinant antibody fragments; antibody-targeted therapy; pretargeting; immunoconjugates; immunoparticles; therapeutic index;

D O I：

10.1089/cbr.2006.21.285

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of recombinant antibodies has facilitated the exploitation of the Ab-Ag interaction specificity for targeted therapies. A fully human antibody, with custom integrated designs, can be obtained in one-third the time, compared to development of antibodies by hybridoma technology. Recombinant antibodies can be tailored for specific applications, "armed" with cytotoxic agents in a controllable fashion, and used for extracellular and intracellular targeting. Multitargeted and combination therapies are rapidly evolving for the treatment of cancer. Antibody therapeutics, costly to develop and produce, have proven beneficial in the clinic.

引用

页码：285 / 304

页数：20

共 141 条

[1] Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab [J].

Adams, CW ;

Allison, DE ;

Flagella, K ;

Presta, L ;

Clarke, J ;

Dybdal, N ;

McKeever, K ;

Sliwkowski, MX .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) :717-727

[2]

Adams GP, 2001, CANCER RES, V61, P4750

[3] Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers [J].

Adams, GP ;

Tai, MS ;

McCartney, JE ;

Marks, JD ;

Stafford, WF ;

Houston, LL ;

Huston, JS ;

Weiner, LM .

CLINICAL CANCER RESEARCH, 2006, 12 (05) :1599-1605

[4] Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu [J].

Adams, GP ;

Schier, R ;

McCall, AM ;

Crawford, RS ;

Wolf, EJ ;

Weiner, LM ;

Marks, JD .

BRITISH JOURNAL OF CANCER, 1998, 77 (09) :1405-1412

[5] Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 [J].

Aktas, Y ;

Yemisci, M ;

Andrieux, K ;

Gürsoy, RN ;

Alonso, MJ ;

Fernandez-Megia, E ;

Novoa-Carballal, R ;

Quiñoá, E ;

Riguera, R ;

Sargon, MF ;

Çelik, HH ;

Demir, AS ;

Hincal, AA ;

Dalkara, T ;

Çapan, Y ;

Couvreur, P .

BIOCONJUGATE CHEMISTRY, 2005, 16 (06) :1503-1511

[6] Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand [J].

Albrecht, H ;

Burke, PA ;

Natarajan, A ;

Xiong, CY ;

Kalicinsky, M ;

DeNardo, GL ;

DeNardo, SJ .

BIOCONJUGATE CHEMISTRY, 2004, 15 (01) :16-26

[7] Characterization of a CC49-based single-chain fragment-β-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT) [J].

Alderson, RF ;

Toki, BE ;

Roberge, M ;

Geng, W ;

Basler, J ;

Chin, R ;

Liu, A ;

Ueda, R ;

Hodges, D ;

Escandon, E ;

Chen, T ;

Kanavarioti, T ;

Babé, L ;

Senter, PD ;

Fox, JA ;

Schellenberger, V .

BIOCONJUGATE CHEMISTRY, 2006, 17 (02) :410-418

[8]

*AMG ABG INC, 2005, ONCOLOGY, V19, P1800

[9] Production technologies for monoclonal antibodies and their fragments [J].

Andersen, DC ;

Reilly, DE .

CURRENT OPINION IN BIOTECHNOLOGY, 2004, 15 (05) :456-462

[10] Recombinant protein expression for therapeutic applications [J].

Andersen, DC ;

Krummen, L .

CURRENT OPINION IN BIOTECHNOLOGY, 2002, 13 (02) :117-123

← 1 2 3 4 5 6 7 8 9 10 →